The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial von Luke, Jason J., Patel, Manish R., Blumenschein, George R., Hamilton, Erika, Chmielowski, Bartosz, Ulahannan, Susanna V., Connolly, Roisin M., Santa-Maria, Cesar A., Wang, Jie, Bahadur, Shakeela W., Weickhardt, Andrew, Asch, Adam S., Mallesara, Girish, Clingan, Philip, Dlugosz-Danecka, Monika, Tomaszewska-Kiecana, Monika, Pylypenko, Halyna, Hamad, Nada, Kindler, Hedy L., Sumrow, Bradley J., Kaminker, Patrick, Chen, Francine Z., Zhang, Xiaoyu, Shah, Kalpana, Smith, Douglas H., De Costa, Anushka, Li, Jonathan, Li, Hua, Sun, Jichao, Moore, Paul A.

Volltext

Immunotherapy for the Treatment of Breast Cancer: Emerging New Data von Mina, Lida A, Lim, Shannon, Bahadur, Shakeela W, Firoz, Abdul T

Volltext

313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms von Patel, Manish, Luke, Jason, Hamilton, Erika, Chmielowski, Bartosz, Blumenschein, George, Kindler, Hedy, Bahadur, Shakeela, Santa-Maria, Cesar, Koucheki, Janine, Sun, Jichao, Kaul, Sanjeev, Chen, Francine, Zhang, Xiaoyu, Muth, John, Kaminker, Patrick, Moore, Paul, Sumrow, Bradley, Ulahannan, Susanna

Volltext

A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma von Wang, Jie, Asch, Adam S., Hamad, Nada, Weickhardt, Andrew, Tomaszewska-Kiecana, Monika, Dlugosz-Danecka, Monika, Pylypenko, Halyna, Bahadur, Shakeela, Ulahannan, Susanna, Koucheki, Janine, Sun, Jichao, Li, Hua, Chen, Francine, Zhang, Xiaoyu, Muth, John, Kaminker, Patrick, Moore, Paul, Sumrow, Bradley James

Volltext

Abstract P1-18-04: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies... von Gradishar, William J., Im, Seock-Ah, Cardoso, Fatima, Cortes, Javier, Curigliano, Giuseppe, Pegram, Mark D., Musolino, Antonino, Berardi, Rosanna, De Laurentiis, Michelino, Bahadur, Shakeela W., Im, Young-Hyuck, Lynch, Cynthia, Novik, Yelena, Edlich, Sutton, Rock, Edwin, Hong, Shengyan, Rugo, Hope S.

Volltext

Abstract PS10-24: Infusion related reactions in the phase 3 SOPHIA trial of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with pretreated HER2+ metastatic b... von Cortes, Javier, Cardoso, Fatima, Curigliano, Giuseppe, Gradishar, William J, Im, Seock-Ah, Rugo, Hope S, Bahadur, Shakeela W, Falcone, Alfredo, Murillo, Serafin Morales, Riseberg, David A, Musolino, Antonino, Feinstein, Trevor M, Abreu, Miguel H, Im, Young-Hyuck, Novik, Yelena, Pluard, Timothy, Salazar, Lupe G, Berardi, Rossana, Pop, Viorela, Hong, Shengyan, Jacobs, Kenneth, Rock, Edwin, Pegram, Mark D

Volltext

A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms von Luke, Jason J., Patel, Manish R., Hamilton, Erika Paige, Chmielowski, Bartosz, Ulahannan, Susanna Varkey, Kindler, Hedy L., Bahadur, Shakeela Wazeen, Clingan, Philip R., Mallesara, Girish, Weickhardt, Andrew James, Currence, Scott, Xu, Linzhi, Kaul, Sanjeev, Chen, Francine, Moore, Paul A., Bonvini, Ezio, Sumrow, Brad, Blumenschein, George

Volltext

SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met)... von Escrivá, Santiago, Im, Seock-Ah, Cardoso, Fatima, Cortes, Javier, Curigliano, Giuseppe, Gradishar, William John, Pegram, Mark D., Wright, Gail Lynn Shaw, Levy, Christelle, De Laurentiis, Michelino, Ferrero, Jean-Marc, Bahadur, Shakeela Wazeen, Kim, Sung-Bae, Petráková, Katarína, Riseberg, David A., Yardley, Denise A., Edlich, Sutton, Hong, Sam, Rock, Edwin P., Rugo, Hope S.

Volltext

SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) af... von Rugo, Hope S., Im, Seock-Ah, Wright, Gail Lynn Shaw, Escriva-de-Romani, Santiago, DeLaurentiis, Michelino, Cortes, Javier, Bahadur, Shakeela Wazeen, Haley, Barbara B., Oyola, Raul H., Riseberg, David A., Musolino, Antonino, Cardoso, Fatima, Curigliano, Giuseppe, Kaufman, Peter A., Pegram, Mark D., Edlich, Sutton, Hong, Sam, Rock, Edwin P., Gradishar, William John

Volltext

Abstract P4-01-16: High levels of RSK2 in breast cancer patients is associated with longer PFS in patients treated with PMD-026, a first in class RSK inhibitor von Wang, Judy S., Beeram, Muralidhar, Chalasani, Pavani, Mina, Lida, Shatsky, Rebecca A., Hurvitz, Sara, Trivedi, Meghna S., Wesolowski, Robert, Han, Hyo S., Patnaik, Amita, Bahadur, Shakeela, Huynh, My-my, Jayanthan, Aarthi, Los, Gerrit, Dunn, Sandra E., Dorr, Andrew

Volltext

Abstract 5385: Thymoquinone(TQ) and cisplatin(CDDP) in a non-small cell lung cancer (NSCLC) xenograft model von Jafri, Syed H., Boyd, Molly, Bahadur, Shakeela, Glass, Jonathan, Shi, Runhua, Kleiner, Heather

Volltext